Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari - CFO Bill Guyer - CDO Charlie Robb - CBO Sean Maduck - President, Corcept Endocrinology Conference Call Participants Ed Nash - Canaccord Dennis Ding - Jefferies Greg Fraser - Truist Alan Leong - BioWatch News Operator Good day, and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call.

Corcept Therapeutics Incorporated (CORT) Q3 2022 Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates

Catalyst Pharmaceuticals

Vertex Pharmaceuticals

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

These 3 Stocks Are Winning the Bear Market -- Here's How

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Corcept (CORT) Thrives on Korlym, Overdependence a Concern

Alpha Metallurgical Resources

Aspen Technology Inc

e.l.f. Beauty

Palomar

Parsons Corp

World Wrestling Entertainment

The markets have delivered one of the worst years in the past several decades. As a result, investors are left searching for under-the-radar stocks that have been passed over due to all the bad news.

7 Under-the-Radar Stocks With 100% Upside Potential

Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.

Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS

MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated DAZALS – a Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 14, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT).If you suffered losses exceeding $50,000 investing in Corcept stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Corcept Investor Alert

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why

Jazz Pharmaceuticals

They're both cornering specialized markets and growing aggressively in the process.

2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Assertio Therapeutics Inc

ASRT vs. CORT: Which Stock Is the Better Value Option?

ASRT or CORT: Which Is the Better Value Stock Right Now?

JAZZ vs. CORT: Which Stock Is the Better Value Option?

JAZZ or CORT: Which Is the Better Value Stock Right Now?

Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.

Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President, and Director Atabak Mokari - Chief Financial Officer Bill Guyer - Chief Development Officer Charlie Robb - Chief Business Officer Sean Maduck - President, Corcept Endocrinology Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. Inc. Dennis Ding - Jefferies Greg Fraser - Truist Securities Arthur He - H.C. Wainwright and Company Alan Leong - BioWatch News Operator Good day, and thank you for standing by.

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2022 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates

Here is how Corcept Therapeutics (CORT) and Alkermes (ALKS) have performed compared to their sector so far this year.

Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Amgen

Regeneron Pharmaceuticals

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. The post 3 Biotech Stocks Outperforming a Bear Market appeared first on InvestorPlace.

3 Biotech Stocks Outperforming a Bear Market

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.

Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns

Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel alone Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel alone

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-corcept-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Corcept Therapeutics Incorporated

Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 18, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT).If you suffered losses exceeding $50,000 investing in Corcept stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Corcept Update

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

Corcept Therapeutics Incorporated. (NASDAQ:CORT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Chris Howerton - Jefferies Edward Nash - Canaccord Genuity Gregory Fraser - Truist Securities Arthur He - H.C.

News for Corcept Therapeutics Stock (CORT)